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Select: GWAS Gets FunctionalBy identifying regions of the human genome linked to complex traits, genome-wide association
studies (GWAS) are revolutionizing how researchers investigate common diseases, such as cancer
and cardiovascular disease. However, as with many great scientific breakthroughs, skeptics have
questioned the usefulness of this approach andwhether GWAScan provide insights into themolec-
ular mechanisms underlying these diseases. This Select highlights recent research showing that
common DNA variations identified by GWAS can indeed contribute to a disease phenotype, and
investigating the function of these variants can be highly rewarding, yielding insights of both clinical
and biological importance.Low-density lipoprotein particle (LDL) (left) and high-
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Approximately 30% of Americans suffer from cardiovascular disease,
and high levels of low-density lipoprotein (LDL) cholesterol in the blood
is one major risk factor for this common disease. Therefore, a major
goal of the pharmaceutical industry is to identify new approaches for
lowering LDL cholesterol. Previous GWAS pinpointed a noncoding
region on chromosome 1, the 1p13 locus, as strongly associated
with increased risk of heart disease and high levels of LDL cholesterol.
Now Musunuru et al. (2010) determine the function of these DNA vari-
ants and, in the process, uncover a new pathway that regulates choles-
terol metabolism. Moreover, they identify a protein, sortilin 1 (SORT1),
that directly reduces the blood levels of LDL cholesterol in mice.
Sequence variations outside coding regions often modulate the
expression of nearby genes. Therefore, Musunuru et al. first profile
the expression of seven genes surrounding the 1p13 locus in humantissue samples. Interestingly, although SORT1 is not the closest gene to the risk allele, its gene expressionwasmost strongly affected
by sequence variations in the disease locus; the allele associated with low levels of LDL cholesterol boosts SORT1 gene expression
by almost 4-fold in the liver. Sequencing and DNA-binding assays reveal that this protective allele, which is120 kb upstream of the
SORT1 promoter, creates a binding site for C/EBPa, a transcription factor that regulates numerous metabolic processes in the liver.
SORT1 is a membrane receptor in the Golgi network that controls intracellular trafficking. To confirm its importance in cholesterol
metabolism, Musunuru and colleagues silence the expression of Sort1 in the liver of mice, which increases LDL cholesterol by 2-fold.
In contrast, overexpressing Sort1 reduces total plasma cholesterol levels by 70%. These results elegantly demonstrate that char-
acterizing the function of risk alleles from a GWAS can have huge payoffs—the discovery of critical components contributing to
a common disease and new targets for treating the disorder.
K. Musunuru et al. (2010). Nature 466, 714–719.Big Sample Size, Big Results
Whereas Musunuru et al. (2010) focus on a small region of chromosome 1, Teslovich et al. (2010) take the opposite approach. They
scale up the search for heart disease genes to one of the largest GWAS ever reported, with >100,000 individuals and 2.6 million
single-nucleotide polymorphisms. Nevertheless, Teslovich et al. then nail down the physiological relevance of three disease loci
using a strategy similar to that of Musunuru et al., and in the process, they also discover potential therapeutic targets for lowering
cholesterol and triglycerides.
Combining data from 46 previous GWAS, Teslovich et al. identify 95 DNA variants associated with levels of particular blood lipids.
Collectively these loci account for 10% of the variation in blood lipid levels observed across individuals, but these alleles don’t
directly pinpoint the genes that influence blood lipid levels. To find these ‘‘causal genes,’’ Teslovich and colleagues then test whether
the identified DNA variants alter the expression of nearby genes in human tissue samples. This ‘‘expression quantitative trait loci’’
(eQTL) analysis uncovers 28 candidate genes, and the authors validate the function of three of these genes in mice models. For
example, they show that a protein phosphatase (PPP1R3B) and an enzyme involved in protein glycosylation (GALNT2) significantly
reduce cholesterol levels when overexpressed in mice.
Together with the study by Musunuru et al. (2010), these results demonstrate that a powerful strategy for identifying the causal
genes of common diseases is to combine GWAS with gene expression profiling (e.g., eQTL analysis). In addition, this study
demonstrates that increasing the sample size of GWAS can be quite fruitful, uncovering many genetic loci with both physiological
and therapeutic relevance.
T.M. Teslovich et al. (2010). Nature 466, 707–713.Cell 143, October 15, 2010 ª2010 Elsevier Inc. 177
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GWAS
Although not as common as cardiovascular disease, chronic kidney disease affects10%
of Americans, and the risk for African Americans is even greater,4 times that of European
Americans. Previous GWAS found that a polymorphism in a myosin motor gene was asso-
ciated with 2–4 times the risk of kidney disease, helping to explain a large proportion of
the increased susceptibility observed in African Americans. Now Genovese et al. (2010)
show that the functional allele actually resides downstream of the myosin gene in the apoli-
poprotein L-1 (APOL1) gene. Moreover, this risk allele appears to have arisen by positive
selection in African Americans because it probably helps to protect individuals fromAfrican
sleeping sickness.
Using data from the 1000 genomes project, Genovese et al. examine a large region of
chromosome 22 in African Americans with and without kidney disease. The strongest
association with kidney disease occurs at two tightly linked polymorphisms in the lastexon of APOL1 (S342 G and I384 M), and two copies of this allele increase an individual’s risk for kidney disease by a whopping
7- to 10-fold. Furthermore, the association between kidney disease and the polymorphisms in the myosin gene disappears when
variations in the APOL1 gene are taken into account.
Surprisingly, the risk alleles in APOL1 appear to confer protection against African sleeping sickness. Previous studies found that
apolipoprotein L-1 can lyse the protozoan Trypanosoma brucei that causes African sleeping sickness. However, one subspecies of T.
brucei has adapted to humans by synthesizing a protein that binds to and inhibits apolipoprotein L-1. Strikingly, the polymorphisms
associated with kidney disease prevent apolipoprotein L-1’s interaction with the parasite protein, allowing this apolipoprotein L-1
variant to lyse the deadly T. brucei subspecies. These APOL1 risk alleles occur in >30%of African Americans. Therefore, deciphering
how apolipoprotein L-1 contributes to kidney disease is clearly an important next step for combating this disease.
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In the three previous studies, the gene underlying a disease was not the one
closest to the locus identified in GWAS but rather a gene farther down- or
upstream. But this isn’t always the case. As Pittman et al. (2010) demonstrate,
sometimes risk variants do indeed fall immediately adjacent to the disease genes
that they influence, even for a complex disease, such as colon cancer.
In a previous GWAS, the authors found that a noncoding region on chromo-
some 8 (8q23.3) increases an individual’s risk for developing colorectal cancer.
Now Pittman et al. provide strong evidence that a short segment in this region
acts as a transcriptional repressor for the adjacent gene, EIF3H, which encodesa subunit of a eukaryotic translation initiation factor that regulates cell growth and survival. Moreover, a single-nucleotide polymor-
phism associated with colorectal cancer obliterates this region’s suppressive activity.
Pittman et al. identify three short segments or ‘‘islands’’ upstream of EIF3H that are highly conserved across mammals. One of
these ‘‘islands’’ acts as an allele-specific repressor of transcription in vitro.When placed upstream of a reporter gene, the native allele
of this region, but not the risk allele linked to colon cancer, markedly reduces the expression of the downstream gene in cancer cell
cultures. A crosslinking technique, called chromosome conformation capture, reveals that this genomic region physically interacts
with the promoter region of EIF3H. Finally, Pittman and colleagues show that enhanced expression of EIF3H increases cellular prolif-
eration in the cell lines, whereas silencing EIF3H reduces colony growth by 40%. Together, these results strongly suggest that the
risk allele upstream of EIF3H probably contributes to the development of colorectal cancer by increasing cell tumor growth through
its upregulation of EIF3H. Clearly, the contributions of GWAS to our understanding of common diseases are only just beginning, and it
will be thrilling to see how the impact of these studies ripple throughout basic and clinical research over the next decade.
A.M. Pittman et al. (2010). PLoS Genet. 6, e1000126.
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